A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 689-692

  Ding, Cuimin ^a   Li, Ruijuan ^a   Peng, Jingcui ^a   Li, Shengmian ^a   Guo, Zhanjun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Microrna; Outcome; SET8; Small cell lung cancer

Indexed keywords

HISTONE METHYLTRANSFERASE; MICRORNA; MICRORNA 502; SET8 PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER PROGNOSIS; CANCER RISK; CLINICAL ARTICLE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOMIC INSTABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863038472     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.469     Document Type: Article

References (26)

1. Adjei AA, Marks RS and Bonner JA: Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 74: 809-816, 1999
2. Simon GR and Wagner H: For the American College of Chest Physicians. Small cell lung cancer. Chest 123 (Suppl): 259S-271S, 2003.
3. National Comprehensive Cancer Network. National Comprehensive Cancer Network practice guidelines in oncology v. 1.2007: small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf. Accessed January 9, 2007.
4. Hyde L, Yee J, Wilson R and Panto ME: Cell type and the natural history of lung cancer. JAMA 193: 52-54, 1965
5. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B and Hansen HH: Long term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 13: 1215-1220, 1995.
6. Rawson NS and Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61: 597-604, 1990.
7. Knez L, Sodja E, Kern I, Košnik M and Cufer T: Predictive value of multidrug resistance protein, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review. Lung Cancer 72: 271-279, 2011.
8. Kin YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y and Ochiai A: Expression of the breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65: 105-111, 2009.
9. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
10. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
11. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicated that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
12. Zeng Y, Yi R and Cullen BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100: 9779-9784, 2003.
13. Zeng Y, Wagner EJ and Cullen BR: Both natural and designed microRNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9: 1327-1333, 2002.
14. Chin LJ, Ratner E, Leng S, et al: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540, 2008.
15. Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, Hemminki K, Lenner P and Försti A: Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 29: 1394-1399, 2008.
16. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M and Shen SH: Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35: 4535-4541, 2007.
17. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F and Landi S: Polymorphisms within microRNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29: 579-584, 2008.
18. Saunders MA, Liang H and Li W-H. Human polymorphism at microRNA and microRNA target sites. Proc Natl Acad Sci USA 9: 3300-3305, 2007.
19. Gao Y, He Y, Ding J, et al: An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30: 2064-2069, 2009.
20. Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, Erdjument-Bromage H, Tempst P, Simon JA and Zhang Y: Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol 12: 1086-1099, 2002.
21. Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P, Tempst P, Steward R, Lis JT, Allis CD and Reinberg D: PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell 9: 1201-1213, 2002.
22. Wu S, Wang W, Kong X, Congdon LM, Yokomori K, Kirschner MW and Rice JC. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev 24: 2531-2542, 2010.
23. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 19: 6292-6300, 2009.
24. Guo Z, Wu C, Wang X, Wang C, Zhang R and Shan B: A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer: Nov 18, 2011. doi: 10.1002/ijc.27352. (E-pub ahead of print).
25. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E and Gozani O: Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 27: 636-46, 2007.
26. Merritt WM, Lin YG, Han LY, et al: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650, 2008.